Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, reported a net loss of $190.9 million for the year ended December 31, 2025, compared to a net loss of $257.6 million for the previous year. The company, which is focused on developing allogeneic T cell product candidates for cancer and autoimmune diseases, has accumulated a deficit of $2.0 billion as of December 31, 2025. The decrease in net loss was primarily driven by a $42.1 million decrease in research and development expenses and an $8.4 million decrease in general and administrative expenses.
The company's research and development expenses totaled $150.2 million in 2025, a decrease from $192.3 million in 2024. This reduction was mainly due to decreased development costs related to the advancement of product candidates, lower personnel-related costs, and reduced facilities and other expenses. General and administrative expenses also decreased to $56.8 million in 2025 from $65.2 million in 2024, primarily due to lower personnel-related costs. Allogene reported having $258.3 million in cash, cash equivalents, and investments as of December 31, 2025, projecting that these funds will sustain operations into the first quarter of 2028.
Key operational developments for Allogene in 2025 included the initiation of a Phase 1 clinical trial for ALLO-329 in autoimmune diseases and the continuation of its Phase 2 ALPHA3 trial for cema-cel in large B-cell lymphoma. The company also completed enrollment in the Phase 1 TRAVERSE trial for ALLO-316 in renal cell carcinoma. A workforce reduction was implemented in May 2025 to focus resources on critical clinical programs. The company is also exploring partnering opportunities to advance the ALLO-316 asset.
Allogene is strategically focused on repositioning its allogeneic CAR T product as a first-line consolidation approach, expanding its platform into autoimmune disease treatment, and building state-of-the-art gene engineering and cell manufacturing capabilities. The company anticipates initial proof-of-concept data for ALLO-329 in June 2026 and MRD clearance data from the interim futility analysis of the ALPHA3 trial in April 2026, with ALPHA3 enrollment expected to be completed by the end of 2027. The company is also exploring opportunities to partner with collaborators on product candidates across its pipeline.
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company developing genetically engineered allogeneic CAR T cell therapies for cancer and autoimmune diseases. Its off-the-shelf T cell products, derived from healthy donors, target antigens like CD19 and CD70 to treat hematologic malignancies, solid tumors, and autoimmune disorders. The company’s platform emphasizes scalable manufacturing, reduced graft-versus-host disease risk, and faster patient access compared to autologous therapies.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.